The FDA's recent move was a giant step toward a calamitous new drug approval policy.

ANew Jersey jury awarded compensationto John McDarby, 77,who sued Merck after suffering a heart attack while taking the pain reliever Vioxx.

Regardless of the intentions, clinical drug trials driven primarily by marketing yield enormous benefits for patients and practitioners.

Two recent books, Marcia Angell's The Truth About Drug Companies and Jerome Kassirer's On the Take are often grouped with other anti-pharmaceutical-industry tracts.

It would be too easy, in an effort to cut costs, to constrict the pipeline that is producing one new wonder drug after another.

Targeted biotech drugs that attack specific biological molecules that cause disease are bringing new benefitsand fomentingpricing dynamics different from those of traditional drugs.

Bill Clinton's proposed drug benefit for Medicare recipients is predicated on driving down the cost of drugs that elderly Americans need.

New research findings and a thorough reassessment of older research indicate that drugs like Vioxx can have many important benefits and great potential for addressing serious problems.